Rhelixa

Based in Tokyo, Japan, Rhelixa Inc. is a biotechnology firm specializing in epigenome analysis to enhance life science research and development. The company was founded in February 2015 by Ryo Nakaki, who serves as the Representative Director, CEO, and CTO. Dr. Nakaki holds a Ph.D. in Engineering from the University of Tokyo, where his research focused on developing computational algorithms for analyzing large-scale epigenome data from next-generation sequencers.

Rhelixa operates on a dual-service model, providing both contract omics analysis and a cloud-based SaaS platform. The primary business involves offering comprehensive research support services to companies and academic institutions. This includes consulting on experimental design, next-generation sequencing, and advanced bioinformatics analysis for various applications like RNA-seq, ChIP-seq, and DNA methylation analysis. By managing everything from sample processing to data interpretation, Rhelixa enables clients in sectors like medicine, cosmetics, and food products to accelerate their R&D cycles. The company serves a substantial client base, with over 572 companies and 368 research institutes utilizing its services for more than 12,647 projects as of May 2025.

A key product is RIAS®, a proprietary cloud-based tool that allows researchers to independently perform statistical analysis and create figures from their data. In a significant expansion, Rhelixa launched its "Epiclock® business" in late 2023. This division leverages the company's biological age assessment technology to support anti-aging research and develop consumer-facing testing services. These services provide an evaluation of the body's degree of aging along with actionable plans for anti-aging interventions.

Financially, Rhelixa has secured approximately $5.58 million in total funding across two major rounds. The initial seed round occurred in November 2018 with participation from Mitsubishi Corporation and Sompo. A subsequent Series B round in August 2024 raised $3.37 million, with investors including Daiwa Corporate Investment, Kirin Health Innovation Fund, and Leave a Nest Capital, aiming to expand the Epiclock® anti-aging business across Japan and Asia.

Keywords: epigenome analysis, omics research, bioinformatics, next-generation sequencing, DNA methylation, biological age, anti-aging, R&D support, life sciences, biotechnology, contract research organization, SaaS, RIAS, Epiclock, transcriptomics, genomics, custom analysis, research consulting, molecular biology, genetic analysis